Easy-to-use blood thinners likely to replace Coumadin
February 07, 2012
For atrial fibrillation patients at risk for stroke
MAYWOOD, Ill. -- Within a few years, a new generation of easy-to-use blood-thinning drugs will likely replace Coumadin for patients with irregular heartbeats who are at risk for stroke, according to a journal article by Loyola University Medical Center physicians.
Unlike Coumadin, the new drugs do not require patients to come in to the clinic on a regular basis to check the dose. Nor do the drugs require extensive dietary restrictions.
First author Sarkis Morales-Vidal, MD, and colleagues describe the new drugs in a review article in the February issue of the journal Expert Reviews. Co-authors are Michael J. Schneck, MD, Murray Flaster, MD, and José Biller, MD. All are in the Department of Neurology, Stroke Program, of Loyola University Chicago Stritch School of Medicine. Biller is department chair.
The new drugs include rivaroxaban (Xarelto®), dabigatran etexilate (Pradaxa®) and apixaban (Eliquis®). They do not share the disadvantages of Coumadin, and may provide equal or superior prevention against clots, Morales and colleagues write.
Atrial fibrillation is the most common form of irregular heartbeat, and a major cause of stroke in the elderly. Electrical signals, which regulate the heartbeat, become erratic. Instead of beating regularly, the upper chambers of the heart quiver. Not all the blood gets pumped out, so clots can form. The clots can migrate to the brain and cause strokes.
More than 3 million Americans have atrial fibrillation, and the number is increasing, due in part to the aging population.
Coumadin's generic name is warfarin. For more than 30 years, the drug had been the only anticoagulant for primary and secondary stroke prevention in patients with atrial fibrillation. But the Food and Drug Administration recently approved dabigatran and rivaroxaban to reduce the risk of stroke and blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. The FDA is considering an application to approve apixaban for the same use.
Coumadin must be carefully monitored. If the dose is too high, a patient could experience excessive bruising and be at higher risk for brain hemorrhages. If the dose is too low, the drug would be ineffective in preventing blood clots. Patients typically must come in at least once a month for a blood test to determine whether the dose needs to be adjusted. Some patients have to come in as often as twice a week.
Coumadin patients also must restrict their diets. For example, they should consume only small amounts of cranberry juice and alcohol and not eat large amounts of foods that are rich in vitamin K, such as spinach, brussels sprouts and green tea.
Disadvantages of the new medications include the limited clinical experience and lack of antidotes, the researchers wrote. The newer drugs are more expensive than Coumadin, but reduce the cost of patient monitoring and blood testing, Morales said.
Dabigatran is an effective alternative to Coumadin for stroke prevention in patients with non-valvular atrial fibrillation. Rivaroxaban is another promising alternative for those patients. Apixaban appears to be better than aspirin for stroke prevention in atrial fibrillation patients who are not candidates for Coumadin therapy, Morales and colleagues wrote.
The authors predict that within the next few years, the new drugs will likely replace Coumadin for long-term anticoagulation in selective patients with non-valvular atrial fibrillation.
Loyola University Health System
Related Atrial Fibrillation Current Events and Atrial Fibrillation News ArticlesSocieties issue recommendations for left atrial appendage occlusion
The American College of Cardiology, Heart Rhythm Society and Society for Cardiovascular Angiography and Interventions today released a new overview on the implantation of left atrial appendage occlusion devices. First ESC recommendations for arrhythmias and chronic kidney disease published
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.Heart patients can stop blood thinners when undergoing elective surgery
Patients with atrial fibrillation who stopped taking blood thinners before they had elective surgery had no higher risk of developing blood clots and less risk of major bleeding compared to patients who were given a "bridge" therapy, according to research led by Duke Medicine.Statins show promise to reduce major complications following lung surgery
The results of a prospective, randomized, placebo-controlled, double-blind trial of patients undergoing elective pulmonary resection was designed to evaluate the effects of statin therapy. Stanford research sheds light on how neurons control muscle movement
Stanford University researchers studying how the brain controls movement in people with paralysis, related to their diagnosis of Lou Gehrig's disease, have found that groups of neurons work together, firing in complex rhythms to signal muscles about when and where to move. Data scientists find connections between birth month and health
Columbia University scientists have developed a computational method to investigate the relationship between birth month and disease risk. Atrial fibrillation after surgery increases risk of heart attacks and strokes
As many as 12 percent of patients undergoing major, non-cardiac surgery experience an irregular heartbeat called atrial fibrillation. EuroPCR 2015: TAVI, safe and effective as surgical valves at 2 years in lower risk patients
Two year outcomes in a study comparing implantation of transcatheter and surgical bioprosthestic aortic valves shows that the less invasive procedure is safe and effective, and comparable to the gold standard, surgical valve replacement, in patients whose operational risk was lower than that of patients studied in the pivotal randomized trials for these new devices.Evidence that electronic cigarettes are effective for smoking cessation long-term is lacking
There is little reliable evidence that electronic cigarettes are effective for long-term smoking cessation, according to a new analysis of the currently available research which was presented at the 2015 American Thoracic Society International Conference. Off-label use of device to prevent stroke in a-fib patients is prevalent, potentially dangerous
The Lariat device, which has been cleared by the U.S. Food and Drug Administration (FDA) for soft tissue approximation (placement of a suture) during surgical procedures, is associated with a significant incidence of death and urgent cardiac surgery during its frequent off-label use to prevent stroke in patients with the irregular heartbeat known as atrial fibrillation.
More Atrial Fibrillation Current Events and Atrial Fibrillation News Articles
Beat Your A-Fib: The Essential Guide to Finding Your Cure: Written in everyday language for patients with Atrial Fibrillation|
by Steve S Ryan PhD (Author), Patti J Ryan (Contributor)
Beat Your A-Fib: The Essential Guide to Finding Your Cure by Steve S. Ryan, PhD
Atrial Fibrillation (A-Fib) is the most common cardiac arrhythmia (abnormal heart rhythm) seen by physicians. Many patients suffering from Atrial Fibrillation have three strikes against them:
1. Their "quality of life" has deteriorated; they are scared or frightened.
2. Many experience side effects from the common drug therapies or simply do not want to live on medication; a cure for their A-Fib hasn't been discussed.
3. Patient information is often out-of-date, incomplete or biased toward a specific pharmaceutical or treatment; much information about new treatment options is written in the language of scientists and doctors.
The author, Dr. Steve Ryan, PhD, a former A-Fib patient,...
Atrial Fibrillation: What You Need to Know: A Beginner's Guide for Patients and Caregivers (Consumer Health Guides Book 1)|
by Eternal Spiral Books, http://EternalSpiralBooks.com
++The Fifth Edition, published September 8, 2014, is now available, with updates on the latest information on atrial fibrillation, including the latest news on dabigatran, (Pradaxa), and rivaroxaban, (Xarelto), two of the blood thinning medications (anticoagulants) often prescribed for patients with atrial fibrillation, plus news on the drug digoxin, and the effectiveness of catheter ablation for AFib.
Atrial Fibrillation is a particular type of irregular heart beat which can have dangerous consequences to your health if left untreated. People with atrial fibrillation, commonly referred to as AF or AFib, are more prone to blood clots, which can lead to heart attack, stroke or even death.
Fortunately, there are a number of effective treatments available for...
Conquer Your A-Fib: How To Beat Atrial Fibrillation|
Conquer your a-fib is a comprehensive guidebook for this very common arrhythmia. Containing a wealth of information and strategies for overcoming a-fib it covers:
An introduction to a-fib, what it is and how it can be treated.
Several causes of atrial fibrillation that you may not be aware of.
Dietary and chemical triggers for a-fib
Nutritional deficiencies as a potential trigger for episodes
Modifiable risk factors for a-fib which can reduce and even cure your arrhythmia.
Real life cases of people who have beaten a-fib.
A Life on Hold: Crossing Paths with Atrial Fibrillation|
by Kevin J Kauffman (Author)
You're going about your daily routine when you suddenly feel an odd squirming in your chest. You quickly realize that it is your heart, flopping around like a fish out of water. What do you do? You probably panic! Maybe you also experience dizziness, nausea, or shortness of breath, or maybe you have no other symptoms at all. But it's still very scary because... it's your heart! This is how chronic atrial fibrillation starts for many of us, and those who develop it often have little to no prior medical history to speak of. Once the demon a-fib has set in, though, we soon find our lives redirected down a dark uncharted path, our days consumed by vain attempts to divine the elusive origins of this mysterious malady as we desperately seek a panacea that can give us back our "normal"... or...
A Simple Guide to Atrial Fibrillation, Treatment and Related Conditions (A Simple Guide to Medical Conditions)|
Ode to Atrial Fibrillation
Atrial Fibrillation is an abnormal irregular heart beat
Lung diseases and hyperthyroidism contributes to it
It is caused by coronary heart disease and other heart condition
Other causes are congenital heart disease and systemic afflictions
Typically there is fast heart beats and sense of palpitations
There may chest pains and difficulty in respiration
There may congestive heart failure and ankle swelling
There are irregular heart beats and fainting
Both atrial chambers are enlarged due to irregular heart conditions
ECG will confirm the presence of atrial fibrillation
Treatment is to prevent the throwing out of blood clots
These blood clots can...
The Magnesium Miracle (Revised and Updated Edition)|
by Carolyn Dean (Author)
REVISED AND UPDATED 2014 EDITION
Magnesium is an essential nutrient, indispensable to your health and well-being. By adding this mineral to your diet, you are guarding against—and helping to alleviate—such threats as heart disease, stroke, osteoporosis, diabetes, depression, arthritis, and asthma. But despite magnesium’s numerous benefits, many Americans remain dangerously deficient. Updated and revised throughout with the latest research, featuring an all-new Introduction, this amazing guide explains the vital role that magnesium plays in your body and life. Inside you will discover
• newly available magnesium supplements that the body absorbs more efficiently
• how calcium can increase the risk of heart disease—and how magnesium can lower it
Atrial Fibrillation (OxCard Library) (Oxford Cardiology Library)|
by Mohammad Shenasa (Editor), A. John Camm (Editor)
Atrial Fibrillation is becoming a twenty-first century epidemic. It remains the most common form of sustained arrhythmia with significant mortality, morbidity and cost to the health care system. It is the most common cause of hospital admissions among all arrhythmias. Its prevalence increases with the aging population and is often associated with many other cardiac and noncardiac conditions, most notably congestive heart failure, hypertension, diabetes, and coronary artery disease. Although significant progress in understanding the epidemiology, natural history and mechanism has been made, the antiarrhythmic therapy in patients with Atrial Fibrillation is less satisfactory.
Management of Atrial Fibrillation: A Practical Approach is the perfect pocket guide for those who care for...
Medifocus Guidebook on: Atrial Fibrillation|
by Inc. Medifocus.com (Author)
The Medifocus Guidebook on Atrial Fibrillation is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Atrial Fibrillation, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Atrial Fibrillation, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and...
Atrial Fibrillation: A Multidisciplinary Approach to Improving Patient Outcomes (Cardiovascular Team Approach)|
by N. A. Mark Estes III (Author), N. A. Mark Estes III (Editor), Albert L. Waldo (Editor), Joseph Alpert (Editor), Lynne T. Braun (Editor), Gerald Fletcher (Editor), Barbara Fletcher (Editor)
Atrial Fibrillation: A Multidisciplinary Approach to Improving Patient Outcomes, provides a current and comprehensive update on path physiology, epidemiology, management strategies of rate control, pharmacologic and nonpharmacologic approaches to rhythm control, risk stratification for stroke and bleeding, anticoagulant therapy, and left atrial occlusion devices. The contributions by experienced internists, cardiologists, electrophysiologists, surgeons, anesthesiologists, pharmacists, internists, nurse practitioners, and nurse educators provide a unique perspective. Case studies of paroxysmal, persistent, and permanent atrial provide clinical context incorporating recent evidence and best practices for the multidisciplinary approach to improving patient outcomes.
Atrial Fibrillation Therapy (Current Cardiovascular Therapy)|
by Gheorghe-Andrei Dan (Editor), Antoni Bayés de Luna (Editor), John Camm (Editor)
The paradigm for atrial fibrillation (AF) management has changed significantly in recent years. A new era has begun for the prevention of one of the most tremendous complication of AF, stroke. Prevention of ischemic stroke in AF patients with oral anticoagulants represents a huge challenge because of the narrow therapeutic change of these drugs, interindividual and intraindividual variability, and the unsatisfactory time in therapeutically range (TTR) with this type of medication.New guidelines have emerged as a result of new mechanisms for initiation and perpetuation for pharmacotherapy to cure AF and trials with new classes of antithrombotic drugs are ongoing. The treatment of AF is still in its infancy, but recent research is revealing how it can be applied with optimal efficacy. This...